First US biosimilar edges towards market.

First US biosimilar edges towards market. - PDF Download Free
270KB Sizes 3 Downloads 12 Views

Recommend Documents

Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.
Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.

Urban segregation and the US heroin market: a quantitative model of anthropological hypotheses from an inner-city drug market.
We hypothesize that the location of highly segregated Hispanic and in particular Puerto Rican neighborhoods can explain how Colombian-sourced heroin, which is associated with a large-scale decade long decline in heroin price and increase in purity, w

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economi